RareCyte Revenue and Competitors
Estimated Revenue & Valuation
- RareCyte's estimated annual revenue is currently $13.2M per year.
- RareCyte received $30.0M in venture funding in August 2017.
- RareCyte's estimated revenue per employee is $155,000
- RareCyte's total funding is $76M.
Employee Data
- RareCyte has 85 Employees.
- RareCyte grew their employee count by 2% last year.
RareCyte's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Sr. VP Engineering | Reveal Email/Phone |
2 | VP, Finance | Reveal Email/Phone |
3 | SVP, Engineering | Reveal Email/Phone |
4 | VP, Biopharma Services R&D | Reveal Email/Phone |
5 | SVP Biopharma Partnerships | Reveal Email/Phone |
6 | VP, Customer Success | Reveal Email/Phone |
7 | SVP, Bio R&D | Reveal Email/Phone |
8 | Head Legal Counsel | Reveal Email/Phone |
9 | Chief Financial Officer | Reveal Email/Phone |
10 | Director, Biopharma Partnerships | Reveal Email/Phone |
RareCyte Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $48.2M | 192 | 9% | N/A | N/A |
What Is RareCyte?
RareCyte is a company focused on characterizing and isolating rare cells from blood. We develop innovative products for applications in life science, pathology and clinical research as well as drug development and diagnostics. Our tools and solutions help answer difficult questions related to cancer, prenatal health, and infectious disease. RareCyte's unique technologies enable convenient preparation and sophisticated multiparametric phenotypic analysis of rare cells including individual rare cell capture and retrieval for genomic analysis.
keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power
$76M
Total Funding
85
Number of Employees
$13.2M
Revenue (est)
2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
RareCyte News
RareCyte, Inc., a Seattle, WA-based Life Sciences company developing and manufacturing proprietary platforms enabling precision biology solutions, raised $24M in financing. Arboretum Ventures led the financing joined by other new investors F-Prime Capital, Logos Capital, and Agilent Technologie ...
Different immune cells imaged on a section of tonsil by the RareCyte Orion platform. Distinct cell types are in green, red and white, cell nuclei are in blue. (RareCyte Image) Seattle-based startup RareCyte announced $24 million in new funding on Thursday to advance its applications for the ana ...
On September 10, 2021, RareCyte, Inc. closed the transaction. The company has received $46,147 in its second and final tranche closing. The company raised a total of $24,046,147 in the transaction from 27 investors.
... and used CyteFinder and CytePicker technology from RareCyte, to which they had access through PerkinElmer, to pick individual trophoblast ...
RareCyte expands liquid biopsy offerings with the RarePlex™ CTC Developer Kit for custom biomarkers, and introduces the next generation ...
Other Companies in Seattle
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.5M | 85 | 55% | N/A |
#2 | $27.5M | 85 | -10% | N/A |
#3 | $27.5M | 85 | 8% | N/A |
#4 | $11.9M | 85 | 0% | $26.3M |
#5 | $15.9M | 85 | 6% | N/A |
RareCyte Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2012-08-24 | $Undisclosed | Undisclosed | Telegraph Hill Partners | Article |
| 2017-08-30 | $30.0M | Undisclosed | 5AM Ventures | Article |